Experimental drug offered to patients with rare neurological disease
Disease control
AVAILABLE
This program provides access to an investigational drug called levacetylleucine for people with Ataxia-Telangiectasia (A-T), a rare and serious neurological disease. It's designed for patients who cannot participate in regular clinical trials and have no satisfactory alternative …
Sponsor: IntraBio Inc • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC